GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Clinical trials for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One-Shot hope for blinding eye disease? new trial underway
Disease control Recruiting nowThis study tests a single injection into the eye of a new drug (SAR446597) for people with geographic atrophy, a progressive form of age-related macular degeneration that causes vision loss. About 104 participants aged 60 and older will be followed for 2 years, with an optional 3…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 02, 2026 04:00 UTC
-
New drug FWY003 aims to halt blinding eye disease
Disease control Recruiting nowThis Phase 2 trial tests FWY003, an experimental drug, in 272 people with geographic atrophy (a form of advanced age-related macular degeneration). The goal is to see if different doses can slow the growth of damaged areas in the eye and preserve vision. Participants receive eith…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to halt blindness from 'Dry' macular degeneration
Disease control Recruiting nowThis Phase 2 trial tests whether adding APL-3007 to the existing drug Syfovre (pegcetacoplan) can better slow geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 240 adults aged 60 and older with the condition will receive e…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Cell therapy trial aims to halt vision loss in dry AMD
Disease control Recruiting nowThis study tests a cell therapy called OpRegen for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. About 60 participants will receive a one-time injection of retinal cells under the retina during eye surgery. The m…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Gene therapy injection aims to halt vision loss in AMD patients
Disease control Recruiting nowThis study tests a single injection of CTx001 gene therapy into the eye for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. The trial involves 75 participants and will monitor safety and whether the treatment can slow d…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Complement Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New shot aims to save sight in advanced macular degeneration
Disease control Recruiting nowThis study tests an experimental drug called ADX-038 in 240 people with geographic atrophy, a form of advanced age-related macular degeneration that causes blind spots. The drug is given as a shot under the skin and is compared to a placebo to see if it can slow the loss of a key…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Eye injection safety tracked in long-term study for vision loss
Disease control Recruiting nowThis study follows people who already received an eye injection of JNJ-81201887 or a sham in earlier studies for geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. The goal is to check long-term safety, including side effects and eye …
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Electric eye therapy: can a home device slow blindness?
Disease control Recruiting nowThis study tests if a device that delivers mild electrical pulses to the eye (transcorneal electrical stimulation) can safely slow the progression of geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. About 70 people aged 60 and olde…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: NA • Sponsor: Okuvision GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Could a tiny zap save your sight? new device trial for dry AMD
Disease control Recruiting nowThis study tests a device that delivers tiny electrical pulses through the eyelid to the back of the eye. The goal is to see if it can safely slow vision loss or improve sight in people with intermediate to advanced dry age-related macular degeneration. One hundred participants w…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: NA • Sponsor: i-Lumen Scientific AUS PTY LTD • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Gene therapy injection aims to slow vision loss from dry AMD
Disease control Recruiting nowThis study tests a new gene therapy (VV-14295) given as an injection into the eye for people with geographic atrophy, a form of advanced dry age-related macular degeneration that causes blind spots. The goal is to see if it is safe and can slow the growth of these blind spots. Ab…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Kriya Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Could a diabetes pill protect eyesight in advanced dry AMD?
Disease control Recruiting nowThis study tests whether dapagliflozin, a drug used for diabetes, can slow the progression of geographic atrophy—an advanced form of dry age-related macular degeneration that causes blind spots. About 70 adults aged 50 and older with this condition will take the drug for 12 month…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New eye drug IZERVAY under Real-World watch: will it slow vision loss?
Knowledge-focused Recruiting nowThis study follows 500 people with geographic atrophy, an advanced form of age-related macular degeneration that causes permanent vision loss. Participants receive avacincaptad pegol (IZERVAY) as part of their routine care. Researchers will collect data on treatment patterns, sid…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Sponsor: Astellas Pharma Global Development, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New study tracks eye disease progression in older adults
Knowledge-focused Recruiting nowThis study observes 75 adults aged 55 and older with geographic atrophy (a late stage of age-related macular degeneration) to see how the condition progresses over a short time. Researchers will measure changes in eye structure and function, and explore links to genetics and life…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Sponsor: Complement Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC